Mianserine Eg (Mianserin Hydrochloride)

Mianserin works by blocking presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine, and by antagonising certain serotonin receptors (5‑HT2 and 5‑HT3). This dual action enhances both norepinephrine and serotonin neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mianserine Eg is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for Mianserin in pregnancy and lactation are limited. It is generally classified as having an unknown pregnancy category, and use is only recommended if the potential benefits outweigh the possible risks to the fetus or infant.

To order Mianserine Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mianserin belongs to the tetracyclic antidepressant class, differing from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) in its receptor‑blocking profile. It may be chosen when patients experience inadequate response or intolerable side effects with other antidepressant classes.

Mianserine Eg should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Mianserine Eg is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole and avoid crushing or chewing it unless specifically instructed.

Serious risks include agranulocytosis, seizures, and cardiac arrhythmias. Patients should promptly report signs of infection, unexplained fever, fainting, palpitations, or any new neurological symptoms to their healthcare provider.

Mianserine Eg is contraindicated in individuals who are currently taking monoamine oxidase inhibitors (MAOIs) or have a known hypersensitivity to Mianserin or any of its excipients. Caution is also advised for patients with severe hepatic impairment or uncontrolled cardiovascular disease.